Neprilysin

Neutral endopeptidase; NEP; Cluster of differentiation 10; CD10

Neprilysin (NEP) is a type II membrane metalloendopeptidase composed of 750 residues with an active site containing a zinc-binding motif (HEXXH) at the extracellular carboxyl terminal domain. Neprilysin is capable of degrading the monomeric and the oligomeric forms of Aβ peptide. Neprilysin is the dominant Aβ peptide-degrading enzyme in the brain; Neprilysin becomes inactivated and down-regulated during both the early stages of Alzheimer's disease (AD) and aging.

Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatatory, and anti-proliferative effects.

Neprilysin Inhibitors

Candoxatril
(UK 79300)

Cat. No.: HY-19649

Candoxatril is a neutral endopeptidase (**NEP**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LCZ696
(Sacubitril/Valsartan)

Cat. No.: HY-18204A

LCZ696 (Sacubitril/Valsartan), comprised Valsartan (an ARB) and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting **angiotensin receptor-neprilysin (ARN)** inhibitor for hypertension and heart failure.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NEP-In-1

Cat. No.: HY-U00294

NEP-IN-1 is a neutral endopeptidase (**NEP**) inhibitor with IC_{50} of 2 nM for **dNEP**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NEP-IN-2

Cat. No.: HY-U00336

NEP-IN-2 is an inhibitor of **neutral endopeptidase**, used in the research of proliferation in atherosclerosis, restenosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phosphoramidon Disodium

Cat. No.: HY-N2021A

Phosphoramidon Disodium is a **metalloprotease** inhibitor. Phosphoramidon inhibits endothelin-converting enzyme (**ECE**), neutral endopeptidase (**NEP**), and angiotensin-converting enzyme (**ACE**) with IC_{50} values of 3.5, 0.034, and 78 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Racecadotril
(Acetorphan)

Cat. No.: HY-17399

Racecadotril (Acetorphan) is a **neutral endopeptidase** (**NEP**) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with K_is of 4500 and 6.1 nM, , respectively. Antidiarrheal agent.



Purity: 98.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g

Sacubitril
(AHU-377)

Cat. No.: HY-15407

Sacubitril (AHU-377) is a potent **NEP** inhibitor with an IC_{50} of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sacubitril hemicalcium salt
(AHU-377 hemicalcium salt)

Cat. No.: HY-15407A

Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent **NEP** inhibitor with an IC_{50} of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Sacubitrilat
(LBQ-657)

Cat. No.: HY-17620

Sacubitrilat is an active **neprilysin** (**NEP**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Sampatrilat
(UK-81252)

Cat. No.: HY-123348

Sampatrilat (UK-81252) is a potent and orally active **vasopeptidase** inhibitor of **ACE** and neutral endopeptidase (**NEP**). Sampatrilat inhibits C-domain ACE (K_i=13.8 nM) 12.4-fold more potent than that for the N-domain (K_i=171.9 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

SCH 42495

Cat. No.: HY-101682

SCH 42495 is an orally active neutral metalloendopeptidase (**NEP**) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester prodrug of SCH 42354.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SCH 42495 racemate

Cat. No.: HY-101682A

SCH 42495 racemate is the racemate of SCH 42495. SCH 42495 is an orally active neutral metalloendopeptidase (**NEP**) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester prodrug of SCH 42354.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SQ28603

(SQ28,603; Squibb 28603)

Cat. No.: HY-U00171

SQ28603 is a potent and selective inhibitor of neutral endopeptidase 3.4.24.11 (**NEP**), an enzyme that degrades atrial natriuretic peptide (ANP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TD-0212 TFA

Cat. No.: HY-114412A

TD-0212 TFA is an orally active dual pharmacology **angiotensin II type 1 receptor (AT_1)** antagonist and **neprilysin (NEP)** inhibitor, with a **pK_i** of 8.9 for AT_1 and a **pIC_{50}** of 9.2 for NEP.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg